prednisolone acetate ophthalmic suspension / Generic mfg. - LARVOL DELTA

PAACK: Pilocarpine Use After Kahook Goniotomy (clinicaltrials.gov) - P3 | N=142 | Recruiting | Sponsor: Montefiore Medical Center | Trial completion date: Dec 2026 ➔ Dec 2028 | Trial primary completion date: Dec 2026 ➔ Jun 2028 | Suspended ➔ Recruiting

Enrollment open • Trial completion date • Trial primary completion date • Cataract • Glaucoma • Ophthalmology

OLYMPIA-1: A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Follicular Lymphoma (clinicaltrials.gov) - P3 | N=462 | Active, not recruiting | Sponsor: Regeneron Pharmaceuticals | Recruiting ➔ Active, not recruiting | Trial completion date: Apr 2029 ➔ Nov 2031 | Trial primary completion date: Apr 2029 ➔ Feb 2028

Enrollment closed • Trial completion date • Trial primary completion date • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology • CD20

PAACK: Pilocarpine Use After Kahook Goniotomy (clinicaltrials.gov) - P3 | N=142 | Suspended | Sponsor: Montefiore Medical Center | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Cataract • Glaucoma • Ophthalmology

OLYMPIA-2: A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma (clinicaltrials.gov) - P3 | N=733 | Active, not recruiting | Sponsor: Regeneron Pharmaceuticals | Recruiting ➔ Active, not recruiting

Enrollment closed • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology • CD20

DEXTENZA in Pediatric Patients Following Retinal Surgery or Laser Treatment Under Anesthesia (clinicaltrials.gov) - P1 | N=16 | Completed | Sponsor: Lejla Vajzovic, MD, FASRS | N=30 ➔ 16 | Recruiting ➔ Completed

Enrollment change • Trial completion • Anesthesia • Pediatrics • Retinal Disorders

DVS: Dropless Pars Plana Vitrectomy Study (clinicaltrials.gov) - P4 | N=168 | Recruiting | Sponsor: Massachusetts Eye and Ear Infirmary | Trial completion date: Jan 2026 ➔ Jan 2027 | Trial primary completion date: Jul 2025 ➔ Jul 2026

Trial completion date • Trial primary completion date • Retinal Disorders

Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking (clinicaltrials.gov) - P1/2 | N=20 | Enrolling by invitation | Sponsor: Maanasa Indaram, MD | Trial completion date: Dec 2024 ➔ Jun 2026 | Trial primary completion date: Dec 2024 ➔ Dec 2025

Trial completion date • Trial primary completion date • Ophthalmology

A Study of the Safety, Tolerability and Prelinminary Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis (clinicaltrials.gov) - P1 | N=16 | Active, not recruiting | Sponsor: Shanghai BDgene Co., Ltd. | Recruiting ➔ Active, not recruiting | Trial completion date: Sep 2025 ➔ Mar 2026

Enrollment closed • Trial completion date • Herpes Simplex • Keratitis • Ocular Inflammation • Ophthalmology

OLYMPIA-3: A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Patients With Previously Untreated Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - P3 | N=904 | Active, not recruiting | Sponsor: Regeneron Pharmaceuticals | Recruiting ➔ Active, not recruiting | Trial completion date: Sep 2028 ➔ Apr 2029 | Trial primary completion date: Sep 2028 ➔ Mar 2028

Enrollment closed • Trial completion date • Trial primary completion date • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20

A Phase 2 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis (clinicaltrials.gov) - P2 | N=89 | Completed | Sponsor: VivaVision Biotech, Inc | Terminated ➔ Completed

Trial completion • Ocular Inflammation • Ophthalmology • Uveitis

A Phase 2 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis (clinicaltrials.gov) - P2 | N=89 | Terminated | Sponsor: VivaVision Biotech, Inc | Trial completion date: Mar 2025 ➔ Dec 2024 | Recruiting ➔ Terminated | Trial primary completion date: Mar 2025 ➔ Dec 2024

Trial completion date • Trial primary completion date • Trial termination • Ocular Inflammation • Ophthalmology • Uveitis

DEXTENZA in Pediatric Patients Following Retinal Surgery or Laser Treatment Under Anesthesia (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Lejla Vajzovic, MD, FASRS | Trial completion date: Apr 2024 ➔ Apr 2025 | Trial primary completion date: Apr 2024 ➔ Apr 2025

Trial completion date • Trial primary completion date • Anesthesia • Pediatrics • Retinal Disorders

Study of Complication Rates in Cataract Surgery Patients Treated With Combined Pre-operative NSAID, OMIDRIA, and Subconjunctival Triamcinolone Acetonide Compared With Peri-operative SOC. (clinicaltrials.gov) - P1/2 | N=94 | Recruiting | Sponsor: Inder Paul Singh, M.D.

New P1/2 trial • Surgery • Cataract • Ophthalmology

A Phase 2 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: VivaVision Biotech, Inc

New P2 trial • Ocular Inflammation • Ophthalmology • Uveitis

CLOSE-3: Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population (clinicaltrials.gov) - P3 | N=60 | Recruiting | Sponsor: Salvat | Trial completion date: Aug 2024 ➔ Dec 2025 | Trial primary completion date: Aug 2024 ➔ Dec 2025

Surgery • Trial completion date • Trial primary completion date • Cataract • Inflammation • Ocular Inflammation • Ophthalmology • Pediatrics

Dextenza in the Post-op Management of Vitreoretinal Surgeries (clinicaltrials.gov) - P4 | N=30 | Recruiting | Sponsor: The Cleveland Clinic | Enrolling by invitation ➔ Recruiting | Trial completion date: Jun 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2023 ➔ Dec 2025

Enrollment status • Surgery • Trial completion date • Trial primary completion date • Inflammation • Ocular Inflammation • Pain

A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression (clinicaltrials.gov) - P2 | N=100 | Recruiting | Sponsor: ImmunoGen, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Ovarian Cancer • Solid Tumor

PAACK: Pilocarpine Use After Kahook Goniotomy (clinicaltrials.gov) - P3 | N=142 | Suspended | Sponsor: Montefiore Medical Center | Recruiting ➔ Suspended

Surgery • Trial suspension • Cataract • Glaucoma • Ophthalmology

OLYMPIA-2: A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma (clinicaltrials.gov) - P3 | N=733 | Recruiting | Sponsor: Regeneron Pharmaceuticals | Trial completion date: Jan 2030 ➔ Jul 2029 | Trial primary completion date: Jan 2030 ➔ Jul 2029

Trial completion date • Trial primary completion date • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology • CD20

A Study of the Safety, Tolerability and Prelinminary Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis (clinicaltrials.gov) - P1 | N=16 | Recruiting | Sponsor: Shanghai BDgene Co., Ltd.

New P1 trial • Stroma • Herpes Simplex • Keratitis • Ocular Inflammation • Ophthalmology

A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression (clinicaltrials.gov) - P2 | N=100 | Not yet recruiting | Sponsor: ImmunoGen, Inc.

New P2 trial • Oncology • Ovarian Cancer • Solid Tumor

Effects of perfluorohexyloctane on the ocular pharmacokinetics of latanoprost and prednisolone acetate after topical administration to rabbits (ARVO 2024) - " Male Dutch Belted rabbits received a single topical ocular dose of either latanoprost ophthalmic solution 0.005% (Group 1), PFHO followed by latanoprost (Group 2), prednisolone acetate ophthalmic suspension 1% (Group 3), or PFHO followed by prednisolone acetate (Group 4)... In this preclinical rabbit study, prior instillation of PFHO had no effect on the ocular PK profile of latanoprost acid or prednisolone, suggesting there would be no impact of PFHO on the efficacy of these medications. Based on these findings, the presence of PFHO on the ocular surface appears unlikely to affect absorption of other topical ocular drops in patients with DED on multiple medications."

PK/PD data • Preclinical • Dry Eye Disease • Ophthalmology

Dextenza for Corneal Crosslinking (clinicaltrials.gov) - P1/2 | N=20 | Enrolling by invitation | Sponsor: Maanasa Indaram, MD | Initiation date: Jan 2024 ➔ Apr 2024

Trial initiation date • Ophthalmology

A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract (clinicaltrials.gov) - P3 | N=65 | Completed | Sponsor: Ocular Therapeutix, Inc. | Recruiting ➔ Completed | Trial completion date: Oct 2022 ➔ Dec 2023 | Trial primary completion date: Aug 2022 ➔ Dec 2023

Surgery • Trial completion • Trial completion date • Trial primary completion date • Cataract • Inflammation • Ocular Inflammation • Ophthalmology • Pain • Pediatrics

SUSTAIN: Prospective Study on DEXTENZA® Safety And Efficacy Following Concomitant MIGS and Cataract Surgery (clinicaltrials.gov) - P4 | N=25 | Terminated | Sponsor: The New York Eye Surgery Center | Completed ➔ Terminated; COVID-19 challenges to recruitment

Surgery • Trial termination • Cataract • Glaucoma • Ophthalmology